CN108409759B - Intermediate, intermediate synthesis method and application - Google Patents
Intermediate, intermediate synthesis method and application Download PDFInfo
- Publication number
- CN108409759B CN108409759B CN201810066677.3A CN201810066677A CN108409759B CN 108409759 B CN108409759 B CN 108409759B CN 201810066677 A CN201810066677 A CN 201810066677A CN 108409759 B CN108409759 B CN 108409759B
- Authority
- CN
- China
- Prior art keywords
- compound
- synthesis
- reaction
- water
- intermediate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001308 synthesis method Methods 0.000 title description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 89
- 238000006243 chemical reaction Methods 0.000 claims abstract description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 45
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 43
- 238000010992 reflux Methods 0.000 claims abstract description 19
- 229940125904 compound 1 Drugs 0.000 claims abstract description 17
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000010438 heat treatment Methods 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical group [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 239000002808 molecular sieve Substances 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000002250 absorbent Substances 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 5
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- NUMQCACRALPSHD-UHFFFAOYSA-N tert-Butyl ethyl ether Natural products CCOC(C)(C)C NUMQCACRALPSHD-UHFFFAOYSA-N 0.000 claims description 4
- 238000003682 fluorination reaction Methods 0.000 abstract description 20
- 230000000269 nucleophilic effect Effects 0.000 abstract description 19
- 238000000926 separation method Methods 0.000 abstract description 14
- 238000000746 purification Methods 0.000 abstract description 8
- 238000010189 synthetic method Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 57
- 229940126214 compound 3 Drugs 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 229940125782 compound 2 Drugs 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 229940125898 compound 5 Drugs 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 239000007789 gas Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 11
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000007664 blowing Methods 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 238000002372 labelling Methods 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000012279 sodium borohydride Substances 0.000 description 10
- 229910000033 sodium borohydride Inorganic materials 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000003480 eluent Substances 0.000 description 8
- 238000011010 flushing procedure Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- -1 aryl hydrogen Chemical compound 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000011261 inert gas Substances 0.000 description 6
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- ZWWNPSADOUWQRL-UHFFFAOYSA-N tert-butyl 2-(benzhydrylamino)acetate Chemical compound C=1C=CC=CC=1C(NCC(=O)OC(C)(C)C)C1=CC=CC=C1 ZWWNPSADOUWQRL-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000006096 absorbing agent Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003444 phase transfer catalyst Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 4
- 238000012879 PET imaging Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 201000007983 brain glioma Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000006257 total synthesis reaction Methods 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007350 electrophilic reaction Methods 0.000 description 2
- 238000007336 electrophilic substitution reaction Methods 0.000 description 2
- HMSWAIKSFDFLKN-UHFFFAOYSA-N hexacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC HMSWAIKSFDFLKN-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 235000006506 Brasenia schreberi Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides an intermediate compound, a synthetic method of the intermediate compound and application of the intermediate compound. The method comprises the following steps: adding compound 1 and dimethyl ammonium hydrochloride into solvent formed by mixing dimethyl sulfoxide and water, and adding K for more than 2 times2CO3Heating and refluxing for 6-36 h; wherein, compound 1: dimethyl ammonium hydrochloride salt: k2CO3In a molar ratio of 1: 1-5: 1-5; after the reaction is finished, the intermediate compound is obtained by separation and purification. The intermediate compound is mainly applied to F-BPA nucleophilic fluorination synthesis.
Description
Technical Field
The invention belongs to the field of radiopharmaceuticals, and particularly relates to a F-BPA nucleophilic fluorination synthesis method, an intermediate and application thereof.
Background
Boron Neutron Capture Therapy (BNCT) is a binary radiotherapy method that involves the administration of a neutron source10B is introduced into body by oral administration or injection, selectively accumulated in cancer cells, and irradiated with neutrons to treat lesion10B generation10B(n,α)7Li nuclear reaction, using α particles thus produced and7li ions kill cancer cells in the cellular range. The first BNCT clinical trial treatment of human brain tumor begins in the early 50 th century, and through decades of exploration, research and clinical experiments, BNCT is considered as an effective method for treating tumor (the 5-year survival rate of treating the superficial glioma reaches 33.3%), compared with the existing methods of surgery, radiotherapy, chemotherapy, immunotherapy and gene therapy for cancer, the BNCT has the advantages of positioningAccurate and remarkable curative effect. At present, in addition to the treatment of glioma, research on the treatment of liver cancer, joint necrosis, melanoma, lung cancer and other diseases is also carried out. This approach has become one of the most effective methods for treating malignant brain gliomas and melanomas.
The brain glioma grows in a nervous system for regulating and controlling the activity of a human body, infiltrative growth is realized, the proliferation speed of brain tumor cells is extremely high, and the existing surgical excision, chemotherapy, radiotherapy, X knife, gamma knife and other therapies cannot achieve good treatment effects. Once symptoms have occurred, the average survival of the patients is only 4-6 months. The optimal effect of tumor therapy is to kill tumor cells without damaging normal cells and tissues. For brain tumors, this goal appears to be even more difficult. The BNCT technology can be used for treating brain tumors, has the characteristics of large local radiation dose, small side effect, wide application range, easy protection and the like, but has great relation between the realization of ideal BNCT treatment and the development level of medicaments.
BPA has encouraging therapeutic effects since the clinical trial in 1987, is a BNCT medicament which is most applied internationally, and has guaranteed effectiveness and safety. The effectiveness of BPA on brain gliomas is undoubted, but the problems of how to quickly obtain in vivo pharmacogenomic data thereof, how to monitor the BPA distribution in a patient in real time during clinical use so as to select the best time for neutron beam irradiation, and the like, become the direction of research efforts of scientists. With the development of PET (positron emission tomography) technology and because it can non-invasively and dynamically observe biochemical and physiological changes of the body from the molecular level in the living state, it is not only one of the best tools for early diagnosis and guidance of treatment of brain diseases, cardiovascular diseases and tumors, but also a powerful means for studying the basic theory and practice of medicine and pharmacology, and is currently the bridge connecting molecular biology and clinical medicine, so that positron-emitting nuclides such as positron-emitting nuclide18F-labeled BPA can not only study the metabolic process of BPA in vivo, but also master the biological distribution state of BPA in vivo in real time through PET imaging, which has great significance for the time selection and treatment effect evaluation of BNCT treatment. Thus, study of18Labeling of F-BPAThe significance of the marking method and the optimized marking condition on the wide development of BNCT technology and the research and development of other BNCT medicines is more important.
18A commonly used method for synthesizing the F-labeled drug is to use a carrier18F]F2Electrophilic reaction method and method of using carrier-free [ alpha ], [18F]F-Nucleophilic substitution method. The electrophilic reaction method has simple labeling method and less steps, but the method uses a gas target, and the product has a carrier and low specific activity; and nucleophilic substitution method using H2 18The O water target has no carrier and high specific activity, overcomes the defects of electrophilic substitution, and has the disadvantages of complex labeling method and more steps. The nucleophilic substitution method using the activity [ 2 ]18F]F-The method is characterized in that the ions and the non-labeled precursor containing a proper leaving group are subjected to nucleophilic substitution reaction to prepare the positron emission medicine, and the key point of the method is to prepare the proper non-labeled precursor. At present, nucleophilic substitution has become international18The main development direction of the preparation research of the F-labeled PET imaging agent.
In particular BPA, for electrophilic fluorination of BPA, of BPA18F direct electrophilic labelling was first reported by Ishiwata et al. At present, the number of the current day,18the preparation of F-BPA is marked by a one-step electrophilic method using an electrophilic fluorinating agent18F]AcOF can effectively and rapidly substitute benzene ring through electrophilic substitution18F is introduced into organic molecules, but the labeling rate is low, and the specific activity at the end of the synthesis is 35-60 MBq/mu mol. The total synthesis time is 80min, and the radiochemical purity is more than 95 percent by HPLC analysis. 2004, the year
Etc. report that a high specific activity can be obtained18F]A process for BPA. The method utilizes the [ 2 ]18F]F-To18F]F2Target post-switch for electrophilic labeling. The amount of the labeling precursor can be reduced from 100 mu mol to 4.8 mu mol by the method, and the using amount of the labeling precursor is greatly reduced. The radiochemical yield of the process is on average 3.4% (by [, ] [, ]18F]F-The initial amount of (c), the specific activity at the end of the synthesis is 0.85-1.52 GBq/. mu.mol. The total synthesis time is 50min, and the product is purified by HPLC analysisGreater than 96%. Coderre et al prepared in 200218F-BPA is studied and combined with T98G glioma cells in vitro, and the result shows that18F-BPA has high binding capacity, and the effectiveness of the F-BPA in glioma imaging in vivo can be deduced. In general, electrophilic fluorination of BPA requires the use of F2Gas, and F2Very active gas, extremely strong corrosivity, special requirements for reaction vessel, larger operation danger coefficient and radioactivity18F2For example, the target system to the synthesis module requires special material equipment, which makes the manufacturing cost high, and the prepared target system and synthesis module are manufactured18F2Require the use of stabilizing F2The gas is carried out, so that stable F (carrier) also exists in a product prepared by subsequent marking, the specific activity of the product is reduced, and the developing effect is influenced.
However, no relevant report is found at home and abroad for the research on the BPA nucleophilic fluorine labeling.
Disclosure of Invention
In order to solve the problems of carrier existence, low specific activity, high manufacturing cost and the like of F-BPA prepared by an electrophilic fluorination method of BPA, the invention provides a nucleophilic fluorination synthesis method of F-BPA, an intermediate synthesis method, an intermediate and application thereof.
The F-BPA nucleophilic fluorination synthesis method comprises the following steps:
synthesis of Compound 2
Compound 1, dimethylammonium hydrochloride (NH (CH)3)2HCl) is added into a solvent formed by mixing dimethyl sulfoxide (DMSO) and water, and K is added into the solvent for more than 2 times2CO3Heating and refluxing for 6-36 h; wherein, compound 1: dimethyl ammonium hydrochloride salt: k2CO3In a molar ratio of 1: 1-5: 1-5; the reaction and the structural formula of the compound 1 are shown as a reaction formula 1; after the reaction is finished, separating and purifying to obtain a compound 2;
synthesis of (di) Compound 3
Under the protection of inert gas, a dichloromethane solution of the compound 2 is mixed with methyl-trifluoromethyl sulfonate (CF)3SO3CH3) Mixing the dichloromethane solution, stirring and reacting for 3-12 h, wherein the ratio of the compound 2: the molar ratio of the methyl-trifluoromethyl sulfonate is 1: 1-5, and the generated reaction is shown as a reaction formula 2; after the reaction is finished, separating and purifying to obtain a compound 3;
synthesis of (III) Compound 4
To K2.2.2(4,7,13,16,21, 24-hexaoxy-1, 10-diazabicyclo [ 8.8.8)]Hexacosane), K2CO3Adding dimethyl sulfoxide into the mixture of KF and KF to dissolve, and stirring at 90-160 deg.C for reaction for more than 0.5 h; dropwise adding dimethyl sulfoxide solution of the compound 3, and carrying out reflux reaction at 90-160 ℃ for more than 15min, wherein the generated reaction is shown as a reaction formula 3; wherein, compound 3: k2.2.2: the molar ratio of KF is 1: 1-2: 1-5; then removing dimethyl sulfoxide, dissolving the remainder with methanol, and passing through a Sep-PakC18 solid phase extraction column; eluting and separating the compound 4 from a Sep-Pak C18 solid phase extraction column;
synthesis of (tetra) Compound 5
Dissolving the compound 4 in water, adding the mixture into a tC18 column, flushing the column with water, and blowing gas to discharge redundant liquid; adding NaBH4Reacting the aqueous solution for more than 2min, flushing the column with water, and blowing out excess liquid by using gas; adding HI water solution to react for more than 2min, discharging redundant liquid with gas, and eluting with toluene to obtain toluene solution dissolved with compound 5; wherein, compound 4: NaBH4: HI in a molar ratio of 1: 1-5: 1-5, wherein the reaction is shown as a reaction formula 4;
(V) Synthesis of Compound 6
To the toluene solution in which compound 5 is dissolved, N- (diphenylmethyl) -glycine tert-butyl ester (Ph) is added2CNCH2CO2 tBu) and a Maruoka chiral phase transfer catalyst are mixed and reacted for more than 5 min; adding HI aqueous solution and KOH aqueous solution, and reacting at 150-200 ℃ for more than 3 min; wherein, compound 5: molar ratio of N- (diphenylmethyl) -glycine tert-butyl ester 1: 1-5, wherein the reaction is shown as a reaction formula 5; after the reaction is finished, separating to obtain a compound 6, namely a target product;
according to an extension, K is used in step (one)2CO3Can be made of Na2CO3Instead.
According to a development, the dimethyl sulfoxide of step (one) can be replaced by acetonitrile or Dimethylformamide (DMF).
According to one extension, the method for separating and purifying the compound 2 in the step (one) comprises the following steps: transferring the reaction solution obtained by the reflux reaction to saturated K2CO3In aqueous solution, removing K after delamination2CO3A layer; extracting the residual liquid with an extractant, washing the obtained extract with water, and removing water and the extractant to obtain a compound 2.
Further, the water removal adopts a water absorbent to absorb water and vacuum drying.
Further, the water absorbing agent may be anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride, or a molecular sieve.
Further, the extractant may be diethyl ether, Tetrahydrofuran (THF), ethyl acetate, or tert-butyl ether.
Further, the inert gas in the step (two) may be nitrogen, helium or argon.
According to an extension, the dichloromethane of step (two) can be replaced by chloroform, ethyl acetate, acetone or methanol.
According to one extension, the method for separating and purifying the compound 3 in the step (II) comprises the following steps: and washing the precipitate obtained by the reaction with dichloromethane at a temperature of below 4 ℃ and diethyl ether at a temperature of below 4 ℃ in sequence to remove impurities, and drying in vacuum to obtain the compound 3.
According to an extension, the dimethyl sulfoxides of step (three) can each be replaced by acetonitrile, Dimethylformamide (DMF) or Tetrahydrofuran (THF).
According to an extension, the methanol of step (three) can be replaced by ethanol, isopropanol, acetone, ethyl acetate or dichloromethane.
According to one development, the elution separation method of step (iii) is: eluting the Sep-Pak C18 solid phase extraction column with diethyl ether, 0.1-2mol/L hydrochloric acid, water and dichloromethane in sequence, collecting eluent generated in the dichloromethane elution process, and removing water and dichloromethane.
Further, the water removal agent is used for absorbing water.
Further, the water absorbing agent may be anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride, or a molecular sieve.
Further, the removal of dichloromethane was performed by rotary evaporation and vacuum drying.
Further, the gas in the step (iv) may be nitrogen, helium or argon.
Further, the concentration of the HI aqueous solution of the step (iv) is 57 wt% or more.
According to an extension, the toluene of step (IV) can be replaced by benzene, xylene or chlorobenzene.
Further, the concentration of the HI aqueous solution in the step (five) is 57 wt% or more.
According to an extension, the KOH of step (five) may be replaced by NaOH or LiOH.
According to one extension, the separation method for separating the compound 6 obtained in the step (five) comprises the following steps: evaporating to remove toluene, dissolving the residue with 20-100 mmol/L acetic acid, adding the obtained solution into a Silican column, eluting with 20-100 mmol/L acetic acid aqueous solution, adding a tC18 column, eluting with 20-100 mmol/L acetic acid aqueous solution, and drying the eluent to obtain the compound 6.
Further, the KF in the step (three) adopts K18F, to synthesize18F-BPA。
According to a further development, the invention also provides an intermediate compound 2 of the formula:
the synthesis method of the intermediate compound 2 comprises the following steps: adding compound 1 and dimethyl ammonium hydrochloride into solvent formed by mixing dimethyl sulfoxide and water, and adding K for more than 2 times2CO3Heating and refluxing for 6-36 h; wherein, compound 1: dimethyl ammonium hydrochloride salt: k2CO3In a molar ratio of 1: 1-5: 1-5; after the reaction is finished, the intermediate compound 2 is obtained by separation and purification.
According to an extension, the K2CO3Can be made of Na2CO3Instead.
According to a development, the dimethyl sulfoxide can be replaced by acetonitrile or dimethylformamide.
According to an extension, the method for isolation and purification to obtain intermediate compound 2 is: transferring the reaction solution obtained by the reflux reaction to saturated K2CO3In aqueous solution, removing K after delamination2CO3A layer; extracting the residual liquid by using an extracting agent, washing the obtained extract liquor with water, and removing water and the extracting agent to obtain an intermediate compound 2.
Further, the water removal adopts a water absorbent to absorb water and vacuum drying.
Further, the water absorbing agent may be anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride, or a molecular sieve.
Further, the extractant may be diethyl ether, Tetrahydrofuran (THF), ethyl acetate, or tert-butyl ether.
Use of the above intermediate compound 2: the method is used for F-BPA nucleophilic fluorination synthesis.
According to a further development, the invention also provides an intermediate compound 3 of the formula:
the synthesis method of the intermediate compound 3 comprises the following steps: under the protection of inert gas, mixing a dichloromethane solution of a compound 2 with a dichloromethane solution of methyl-trifluoromethyl sulfonate, and stirring for reaction for 3-12 h, wherein the ratio of the compound 2: the molar ratio of the methyl-trifluoromethyl sulfonate is 1: 1-5; after the reaction is finished, the intermediate compound 3 is obtained by separation and purification.
Use of the above intermediate compound 3: the method is used for F-BPA nucleophilic fluorination synthesis.
According to a further development, the invention also provides an intermediate compound 4 of the formula:
the synthesis method of the intermediate compound 4 comprises the following steps: to K2.2.2, K2CO3And K18Dropwise adding dimethyl sulfoxide into the mixture of F to dissolve the dimethyl sulfoxide, and stirring and reacting at 90-160 ℃ for more than 0.5 h; dropwise adding dimethyl sulfoxide solution of the compound 3, and carrying out reflux reaction at 90-160 ℃ for more than 15 min; wherein, compound 3: k2.2.2: k18The molar ratio of F is 1: 1-2: 1-5; then removing dimethyl sulfoxide, dissolving the remainder with methanol, and passing through a Sep-Pak C18 solid phase extraction column; the intermediate compound 4 is eluted and separated from a Sep-Pak C18 solid phase extraction column.
Use of the above intermediate compound 4: the method is used for F-BPA nucleophilic fluorination synthesis.
According to an extension, the invention also provides an intermediate compound 5 having the following structural formula:
the synthesis method of the intermediate compound 5 comprises the following steps: dissolving the compound 4 in water, adding the mixture into a tC18 column, flushing the column with water, and blowing gas to discharge redundant liquid; adding NaBH4Reacting the aqueous solution for more than 2min, flushing the column with water, and blowing out excess liquid by using gas; adding HI water solution to react for more than 2min, discharging redundant liquid with gas, and eluting with toluene to obtain toluene solution dissolved with intermediate compound 5; wherein, compound 4: NaBH4: HI in a molar ratio of 1: 1-5: 1 to 5.
Use of the above intermediate compound 5: the method is used for F-BPA nucleophilic fluorination synthesis.
The invention adopts a nucleophilic substitution method to synthesize F-BPA, and the nucleophilic fluorination process adopts stable F-Or radioactive18F-Is a nucleophilic attack reagent, avoids F2The hazard of gases. Preparation of radioactivity18F-The stable F carrier band is not needed, so that stable F (carrier) is not introduced into a product prepared by subsequent labeling, namely the obtained product has no carrier, and therefore, the specific activity is high, and the PET imaging quality can be obviously improved.18The radiochemical synthesis time in the preparation process of F-BPA does not exceed 100min, the radiochemical purity can reach 98 percent, and the requirement of better satisfying18The requirements of clinical application of F-BPA.
Drawings
FIG. 1 is a graph of a sample obtained in example 2 of the present invention18Radiochemical map of F-BPA.
Detailed Description
The technical scheme of the invention is further specifically described by the following embodiments and the accompanying drawings. In the following detailed description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the embodiments of the invention. It may be evident, however, that one or more embodiments may be practiced without these specific details. Although the present invention has been described in connection with the accompanying drawings, the embodiments disclosed in the drawings are intended to be illustrative of embodiments of the invention and should not be construed as limiting the invention.
According to one embodiment of the present invention, there is provided a process for the nucleophilic fluorination synthesis of F-BPA, the process comprising the steps of:
synthesis of Compound 2
Adding compound 1 and dimethyl ammonium hydrochloride into solvent formed by mixing dimethyl sulfoxide and water, and adding K for more than 2 times2CO3Heating and refluxing for 6-36 h; wherein, compound 1: dimethyl ammonium hydrochloride salt: k2CO3In a molar ratio of 1: 1-5: 1-5; the reaction and the structural formula of the compound 1 are shown as a reaction formula 1; after the reaction is finished, the compound 2 is obtained by separation and purification.
Synthesis of (di) Compound 3
Under the protection of inert gas, mixing a dichloromethane solution of a compound 2 with a dichloromethane solution of methyl-trifluoromethyl sulfonate, and stirring for reaction for 3-12 h, wherein the ratio of the compound 2: the molar ratio of the methyl-trifluoromethyl sulfonate is 1: 1-5, and the generated reaction is shown as a reaction formula 2; after the reaction is finished, the compound 3 is obtained by separation and purification.
Synthesis of (III) Compound 4
To K2.2.2, K2CO3Adding dimethyl sulfoxide into the mixture of KF and KF to dissolve, and stirring at 90-160 deg.C for reaction for more than 0.5 h; dropwise adding dimethyl sulfoxide solution of the compound 3, and carrying out reflux reaction at 90-160 ℃ for more than 15min, wherein the generated reaction is shown as a reaction formula 3; wherein, compound 3: k2.2.2: the molar ratio of KF is 1: 1-2: 1-5; then removing dimethyl sulfoxide, dissolving the remainder with methanol, and passing through a Sep-Pak C18 solid phase extraction column; the compound 4 was eluted from the Sep-Pak C18 solid phase extraction column.
Synthesis of (tetra) Compound 5
Dissolving the compound 4 in water, adding the mixture into a tC18 column, flushing the column with water, and blowing gas to discharge redundant liquid; adding NaBH4Reacting the aqueous solution for more than 2min, flushing the column with water, and blowing out excess liquid by using gas; adding HI water solution to react for more than 2min, discharging redundant liquid with gas, and eluting with toluene to obtain toluene solution dissolved with compound 5; wherein, compound 4: NaBH4: HI in a molar ratio of 1: 1-5: 1-5, wherein the reaction is shown as a reaction formula 4;
(V) Synthesis of Compound 6
Adding N- (diphenylmethyl) -glycine tert-butyl ester and a Maruoka chiral phase transfer catalyst into the toluene solution in which the compound 5 is dissolved, mixing, and reacting for more than 5 min; adding HI aqueous solution and KOH aqueous solution, and reacting at 150-200 ℃ for more than 3 min; wherein, compound 5: molar ratio of N- (diphenylmethyl) -glycine tert-butyl ester 1: 1-5, wherein the reaction is shown as a reaction formula 5; after the reaction is finished, a compound 6, namely a target product, is obtained by separation.
According to one example, K is used in step (one)2CO3Can be made of Na2CO3Instead.
According to one example, the dimethyl sulfoxide of step (one) may be replaced by acetonitrile or dimethylformamide.
According to an example, the method for separating and purifying the compound 2 in the step (one) comprises the following steps: transferring the reaction solution obtained by the reflux reaction to saturated K2CO3In aqueous solution, removing K after delamination2CO3A layer; using an extracting agent to remove the residueExtracting the liquid, washing the obtained extract with water, and removing water and an extracting agent to obtain a compound 2.
Further, the water removal adopts a water absorbent to absorb water and vacuum drying.
Further, the water absorbing agent may be anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride, or a molecular sieve.
Further, the extractant may be diethyl ether, tetrahydrofuran, ethyl acetate, or tert-butyl ether.
Further, the inert gas in the step (two) may be nitrogen, helium or argon.
According to one example, the dichloromethane of step (two) may be replaced by chloroform, ethyl acetate, acetone or methanol.
According to an example, the method for separating and purifying the compound 3 in the step (ii) comprises the following steps: and washing the precipitate obtained by the reaction with dichloromethane at a temperature of below 4 ℃ and diethyl ether at a temperature of below 4 ℃ in sequence to remove impurities, and drying in vacuum to obtain the compound 3.
According to an example, all the dimethylsulfoxide of step (three) can be replaced by acetonitrile, dimethylformamide or tetrahydrofuran.
According to one example, the methanol of step (three) may be replaced by ethanol, isopropanol, acetone, ethyl acetate or dichloromethane.
According to one example, the elution separation method in the step (three) is as follows: eluting the Sep-Pak C18 solid phase extraction column with diethyl ether, 0.1-2mol/L hydrochloric acid, water and dichloromethane in sequence, collecting eluent generated in the dichloromethane elution process, and removing water and dichloromethane.
Further, the water removal agent is used for absorbing water.
Further, the water absorbing agent may be anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride, or a molecular sieve.
Further, the removal of dichloromethane was performed by rotary evaporation and vacuum drying.
Further, the gas in the step (iv) may be nitrogen.
Further, the concentration of the HI aqueous solution of the step (iv) is 57 wt% or more.
According to one example, the toluene of step (iv) may be replaced by benzene, xylene or chlorobenzene.
Further, the concentration of the HI aqueous solution in the step (five) is 57 wt% or more.
According to one example, the KOH of step (five) may be replaced by NaOH or LiOH.
According to an example, the separation method for separating the compound 6 in the step (five) is as follows: evaporating to remove toluene, dissolving the residue with 20-100 mmol/L acetic acid, adding the obtained solution into a Silican column, eluting with 20-100 mmol/L acetic acid aqueous solution, adding a tC18 column, eluting with 20-100 mmol/L acetic acid aqueous solution, and drying the eluent to obtain the compound 6.
Further, the KF in the step (three) adopts K18F, to synthesize18F-BPA。
According to one example, the present invention also provides an intermediate compound 2 having the formula:
the synthesis method of the intermediate compound 2 comprises the following steps: adding compound 1 and dimethyl ammonium hydrochloride into solvent formed by mixing dimethyl sulfoxide and water, and adding K for more than 2 times2CO3Heating and refluxing for 6-36 h; wherein, compound 1: dimethyl ammonium hydrochloride salt: k2CO3In a molar ratio of 1: 1-5: 1-5; after the reaction is finished, the intermediate compound 2 is obtained by separation and purification.
Use of the above intermediate compound 2: the method is used for F-BPA nucleophilic fluorination synthesis.
According to one example, the present invention also provides an intermediate compound 3 having the formula:
the synthesis method of the intermediate compound 3 comprises the following steps: under the protection of inert gas, mixing a dichloromethane solution of a compound 2 with a dichloromethane solution of methyl-trifluoromethyl sulfonate, and stirring for reaction for 3-12 h, wherein the ratio of the compound 2: the molar ratio of the methyl-trifluoromethyl sulfonate is 1: 1-5; after the reaction is finished, the intermediate compound 3 is obtained by separation and purification.
Use of the above intermediate compound 3: the method is used for F-BPA nucleophilic fluorination synthesis.
According to one example, the present invention also provides an intermediate compound 4 having the formula:
the synthesis method of the intermediate compound 4 comprises the following steps: to K2.2.2, K2CO3And K18Dropwise adding dimethyl sulfoxide into the mixture of F to dissolve the dimethyl sulfoxide, and stirring and reacting at 90-160 ℃ for more than 0.5 h; dropwise adding dimethyl sulfoxide solution of the compound 3, and carrying out reflux reaction at 90-160 ℃ for more than 15 min; wherein, compound 3: k2.2.2: k18The molar ratio of F is 1: 1-2: 1-5; then removing dimethyl sulfoxide, dissolving the remainder with methanol, and passing through a Sep-Pak C18 solid phase extraction column; the intermediate compound 4 is eluted and separated from a Sep-Pak C18 solid phase extraction column.
Use of the above intermediate compound 4: the method is used for F-BPA nucleophilic fluorination synthesis.
According to one example, the present invention also provides an intermediate compound 5 having the formula:
the synthesis method of the intermediate compound 5 comprises the following steps: dissolving the compound 4 in water, adding the mixture into a tC18 column, flushing the column with water, and blowing gas to discharge redundant liquid; adding NaBH4Reacting the aqueous solution for more than 2min, flushing the column with water, and blowing out excess liquid by using gas; adding HI water solution to react for 2min, discharging redundant liquid by using gas, and eluting by using toluene to obtain a toluene solution dissolved with the intermediate compound 5; wherein, compound 4: NaBH4: HI in a molar ratio of 1: 1-5: 1 to 5.
Use of the above intermediate compound 5: the method is used for F-BPA nucleophilic fluorination synthesis.
Example 1:
this example relates to the nucleophilic fluorination synthesis of F-BPA, the synthesis process comprising the following steps:
synthesis of Compound 2
In a three-necked flask, 0.84g of Compound 1, 0.82g of dimethylammonium hydrochloride, and 0.83g K g of dimethyl ammonium chloride were added2CO3Adding a reaction solvent consisting of 20mL of dimethyl sulfoxide and 8mL of water, carrying out reflux reaction for 2h, and adding 0.55g K through a side port2CO3Continuing the reflux reaction for 4h, cooling the reaction solution to room temperature, stopping the reaction, adding 40mL of saturated K into the reaction solution2CO3In the aqueous solution, the reaction solution was separated into two layers, and K for separation was separated by a separatory funnel2CO3The remaining reaction solution was extracted twice with 30mL of ether, the ether layers were combined, washed once with 30mL of water, and dried over anhydrous magnesium sulfate overnight. And (3) filtering to remove anhydrous magnesium sulfate, carrying out rotary evaporation on the diethyl ether liquid to dryness to obtain a light yellow solid, and carrying out vacuum drying to obtain the compound 2. The compound 2 is yellow powder, the yield of the step is 61 percent,1HNMR、13the CNMR spectrum shows correct structure.1HNMR (400MHz, dimethylsulfoxide) (ppm)2.06(s,6H, -CH3)2.49(s, solvent peak), 2.85(s,2H, -B-OH),6.80,6.82,7.68(3H, aryl hydrogen), 10.24(s,1H, -CHO).13CNMR (dimethyl sulfoxide) (ppm)190.0,146.2,135.3,131.1,121.2,119.4,114.2, 43.6.
Synthesis of (di) Compound 3
In a three-necked flask, 0.97g of Compound 2 was added, and dissolved in 15mL of methylene chloride2Under protection, a solution of 1.64g of methyl-trifluoromethyl sulfonate dissolved in 2mL of dichloromethane is added, the reaction is stirred for 3 hours at room temperature, the reaction liquid gradually changes from light yellow to green and finally to red, and a large amount of precipitate appears in the reaction liquid. The precipitate was filtered and washed with cold 20mL of dichloromethane and 50mL of ether, respectively, and the precipitate gradually turned white,vacuum drying to obtain compound 3. Compound 3 was in the form of a white powder with a yield of 88% for this step.1HNMR、13The CNMR spectrum shows correct structure.1HNMR (400MHz, dimethylsulfoxide) (ppm)2.34(s,9H, -CH)3) 3.25(s,2H, -B-OH),7.19,7.21,7.45, (3H, aryl hydrogen), 10.31(s,1H, -CHO).13CNMR (dimethyl sulfoxide) (ppm)193.1,149.2,138.6,136.1,130.5,129.0,125.3,62.8, 26.8.
Synthesis of (III) Compound 4
In a three-necked flask, 1.67g of K2.2.2 and 0.5g K were charged2CO3438mg KF, adding 30mL of anhydrous dimethyl sulfoxide from a dropping funnel for dissolution, heating and stirring the mixture for reaction for 1h at the temperature of 120-130 ℃ in an oil bath, dissolving 1.05g of the compound 3 in 10mL of anhydrous dimethyl sulfoxide, slowly dropping the mixture into the reaction solution from the dropping funnel, changing the reaction solution into deep caramel along with the dropping of the compound 3, refluxing the mixture at the temperature of 120-130 ℃, stirring the mixture for reaction for 30min, stopping the reaction, cooling the mixture to room temperature, distilling the mixture under reduced pressure to remove the solvent dimethyl sulfoxide, dissolving the distillation residue in methanol, passing the mixture through a Sep-Pak C18 solid-phase extraction column, respectively eluting the mixture with diethyl ether, 0.5mol/L HCl solution and water, finally eluting the mixture with dichloromethane, adding anhydrous magnesium sulfate into the eluent for drying, filtering, carrying out rotary evaporation on the filtrate to dryness to obtain a yellow brown solid, and carrying out. Compound 4 was a pale yellow powder with a yield of 57% over this step.1HNMR、13The CNMR spectrum shows correct structure.1HNMR (400MHz, dimethyl sulfoxide) (ppm)2.09(s,2H, -B-OH),2.51(s, solvent peak), 7.49,7.51,8.12(3H, aryl hydrogen), 10.32(s,1H, -CHO).13CNMR (dimethylsulfoxide): 193.0,163.1,136.2,131.4,125.8,124.4,116.5 (ppm).
Synthesis of (tetra) Compound 5
1.05g of Compound 4 was dissolved in water to 6mL, and the solution was applied to a pretreated tC18 column, which was then washed with 20mL of water, and excess liquid was purged with nitrogen. Slowly add 3mL NaBH4The solution (100mg/mL) was reacted for 2min, the column was flushed with water, and excess liquid was removed by blowing with nitrogen for 15 s. 1mL of HI (57 wt%) solution was slowly added, the reaction was carried out at room temperature for 2min, excess liquid was purged with nitrogen, and 15mL of toluene was added to elute Compound 5. The yield of compound 5 was 77%.1HNMR、13The CNMR spectrum shows correct structure.1HNMR (400MHz, dimethyl sulfoxide) (ppm)1.99(s,2H, -B-OH),4.44(s,2H, -CH)2)7.89,8.14,8.22(3H, aryl hydrogen).13CNMR (dimethylsulfoxide): 162.3,133.1,129.2,126.4,124.8,116.5 (ppm).
(V) Synthesis of Compound 6
Transferring the toluene eluent into a reaction bottle, adding 1.5g of N- (diphenylmethyl) -glycine tert-butyl ester and 5mg of Maruoka chiral phase transfer catalyst, fully mixing, reacting at room temperature for 5min, adding 1.50mL of HI (57 wt%) solution and 1mL of 9mol/L KOH solution, capping, heating to 180 ℃, reacting for 3min, heating to evaporate the solvent, dissolving the residue with 50mmol/L acetic acid, adding a pretreated Silican column and a tC18 column, eluting with 50mmol/L acetic acid, carrying out rotary evaporation on the eluent until the eluent is dried, and carrying out vacuum drying to obtain the compound 6. Compound 6 was in the form of a white powder with a yield of 86%.1HNMR、13The CNMR and MS spectrograms show that the structure is correct.1HNMR(400MHz,TFA):(ppm)1.98(s,1H,CH),2.34(2H,-CH2),3.32(s,2H,NH2) 4.06(s,2H, -B-OH),7.32,7.51,8.12(3H, aryl hydrogen), 11.13(s,1H, -COOH).13CNMR (TFA) (ppm)177.0,162.1,141.9,130.2,124.4,115.1,112.8,62.5, 39.4. So far, F-L-BPA is prepared by a nucleophilic fluorination substitution method through continuous 5-step organic synthesis reaction, the total yield reaches 20%, and the total reaction time is about 2 hours.
Example 2
The present embodiment relates to18The nucleophilic fluorination synthesis of F-BPA, the synthesis process comprises the following steps:
synthesis of Compound 2
In a three-necked flask, 0.84g of Compound 1, 0.82g of dimethylammonium hydrochloride, and 0.83g K g of dimethyl ammonium chloride were added2CO3Adding a reaction solvent consisting of 20mL of dimethyl sulfoxide and 8mL of water, carrying out reflux reaction for 2h, and adding 0.55g K through a side port2CO3Continuing the reflux reaction for 4h, cooling the reaction solution to room temperature, stopping the reaction, adding 40mL of saturated K into the reaction solution2CO3In the aqueous solution, the reaction solution was separated into two layers, and K for separation was separated by a separatory funnel2CO3The remaining reaction solution was extracted twice with 30mL of ether, the ether layers were combined, washed once with 30mL of water, and dried over anhydrous magnesium sulfate overnight. Filtering to removeAnhydrous magnesium sulfate and ethyl ether liquid are evaporated to be dry to obtain light yellow solid, and the compound 2 is obtained after vacuum drying. The compound 2 is yellow powder, the yield of the step is 61 percent,1HNMR、13the CNMR spectrum shows correct structure.1HNMR (400MHz, dimethylsulfoxide) (ppm)2.06(s,6H, -CH3)2.49(s, solvent peak), 2.85(s,2H, -B-OH),6.80,6.82,7.68(3H, aryl hydrogen), 10.24(s,1H, -CHO).13CNMR (dimethylsulfoxide): 190.0 (ppm),
146.2,135.3,131.1,121.2,119.4,114.2,43.6。
synthesis of (di) Compound 3
In a three-necked flask, 0.97g of Compound 2 was added, and dissolved in 15mL of methylene chloride2Under protection, a solution of 1.64g of methyl-trifluoromethyl sulfonate dissolved in 2mL of dichloromethane is added, the reaction is stirred for 3 hours at room temperature, the reaction liquid gradually changes from light yellow to green and finally to red, and a large amount of precipitate appears in the reaction liquid. The precipitate was filtered, washed with cold 20mL of dichloromethane and 50mL of ether, and the precipitate gradually turned white and dried in vacuo to give Compound 3. Compound 3 was in the form of a white powder with a yield of 88% for this step.1HNMR、13The CNMR spectrum shows correct structure.1HNMR (400MHz, dimethylsulfoxide) (ppm)2.34(s,9H, -CH)3) 3.25(s,2H, -B-OH),7.19,7.21,7.45, (3H, aryl hydrogen), 10.31(s,1H, -CHO).13CNMR (dimethyl sulfoxide) (ppm)193.1,149.2,138.6,136.1,130.5,129.0,125.3,62.8, 26.8.
Synthesis of (III) Compound 4
Produced by an accelerator18F-mu.L of the solution (activity about 25mCi) was loaded onto an activated QMA column using K2.2.2/K in preparation2CO3mu.L of the solution (K2.2.2 content: 8.85. mu. mol) was eluted into a glass reaction flask, the flask was heated to near dryness in a heating block at 120 ℃ and then heated to near dryness by adding 100. mu.L of acetonitrile (repeated 3 times). After the last evaporation to dryness, after the reaction flask was cooled, a solution of 2.1mg (6.0. mu. mol) of Compound 3 in 500. mu.L of anhydrous dimethylsulfoxide was added to the residue, and the reaction flask was heated to 140 ℃ on a heating block and reacted for 10min to give Compound 4'.
Synthesis of (tetra) Compound 5
The compound 4' in the reaction flask was diluted to 3mL with water, loaded onto a pretreated tC18 column, and the column was washed with 10mL of water and purged with nitrogen for 15 seconds to remove excess liquid. Slowly add 1mL NaBH4The solution (1mg/mL) was reacted for 2min, the column was flushed with water, and excess liquid was removed by blowing with nitrogen for 15 s. mu.L of HI (57 wt%) solution was slowly added, the reaction was carried out at room temperature for 2min, excess liquid was purged with nitrogen, and 3mL of toluene was added to elute the compound 5'.
(V) Synthesis of Compound 6
Transferring toluene eluate to a reaction flask, adding 3mg (10.2. mu. mol) of N- (diphenylmethyl) -glycine tert-butyl ester 3mg (10.2. mu. mol) and Maruoka chiral phase transfer catalyst 0.5mg, mixing thoroughly, reacting at room temperature for 5min, adding HI (57 wt%) solution 150. mu.L and 9mol/L KOH solution 100. mu.L, heating to 180 deg.C, reacting for 3min, heating to evaporate solvent toluene, dissolving residue with 50mmol/L acetic acid, adding pretreated Silican column and tC18 column, and eluting with 50mmol/L acetic acid to obtain compound 618F-L-BPA。
Through a plurality of steps of organic synthesis reactions,18the total synthesis time of F-BPA was about 100min, and the synthesis was complete to give 130MBq product (corrected for decay) with a radiochemical yield of about 26%. The radiochemical purity of the product is determined by thin-layer chromatography, spotted on silica gel thin-layer plates and treated with an aqueous ammonium acetate solution (10 mmol. multidot.L concentration)-1): and developing the mixture solution of 30:70 (volume ratio) of acetonitrile serving as a developing agent, and measuring a radiochemical map of the mixture solution by a mini-scan radioactive thin-layer scanner after air drying, wherein the result shows that the radiochemical purity of the prepared product reaches 98%.
Although a few embodiments in accordance with the present general inventive concept have been shown and described, it would be appreciated by those skilled in the art that changes may be made in these embodiments without departing from the principles and spirit of the general inventive concept, the scope of which is defined in the claims and their equivalents.
Claims (8)
1. An intermediate compound characterized by the following structural formula:
2. a process for the synthesis of an intermediate compound as claimed in claim 1, comprising the steps of: adding compound 1 and dimethyl ammonium hydrochloride into solvent formed by mixing dimethyl sulfoxide and water, and adding K for more than 2 times2CO3Heating and refluxing for 6-36 h; wherein, compound 1: dimethyl ammonium hydrochloride salt: k2CO3In a molar ratio of 1: 1-5: 1-5; after the reaction is finished, separating and purifying to obtain an intermediate compound; the structural formula of the compound 1 is as follows:
3. the method of synthesis of claim 2, wherein: said K2CO3From Na2CO3Instead.
4. The method of synthesis of claim 2, wherein: the dimethyl sulfoxide is replaced by acetonitrile or dimethylformamide.
5. The method of synthesis according to any one of claims 2 to 4, wherein: the method for separating and purifying to obtain the intermediate compound comprises the following steps: transferring the reaction solution obtained by the reflux reaction to saturated K2CO3In aqueous solution, removing K after delamination2CO3A layer; extracting the residual liquid with an extractant, washing the obtained extract with water, and removing water and the extractant to obtain an intermediate compound.
6. The method of synthesis of claim 5, wherein: and the water removal adopts a water absorbent to absorb water and vacuum drying.
7. The method of synthesis of claim 6, wherein: the water absorbent is anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride or a molecular sieve.
8. The method of synthesis of claim 5, wherein: the extractant is diethyl ether, tetrahydrofuran, ethyl acetate or tert-butyl ether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810066677.3A CN108409759B (en) | 2018-01-24 | 2018-01-24 | Intermediate, intermediate synthesis method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810066677.3A CN108409759B (en) | 2018-01-24 | 2018-01-24 | Intermediate, intermediate synthesis method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108409759A CN108409759A (en) | 2018-08-17 |
| CN108409759B true CN108409759B (en) | 2020-10-09 |
Family
ID=63126282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810066677.3A Active CN108409759B (en) | 2018-01-24 | 2018-01-24 | Intermediate, intermediate synthesis method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108409759B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1345720A (en) * | 2000-09-29 | 2002-04-24 | 中国科学院上海原子核研究所 | Process for preparing trifluoromethyl sulfoacid 2-trimethylammonium-4,5-dimethoxy-benzaldehyde |
| JP2016204314A (en) * | 2015-04-23 | 2016-12-08 | 国立研究開発法人理化学研究所 | Compound and method for producing 4-boronophenylalanine derivative |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105592929B (en) * | 2013-09-04 | 2018-06-26 | 美卓矿物公司 | Mineral material processing equipment and the method for operating process equipment |
-
2018
- 2018-01-24 CN CN201810066677.3A patent/CN108409759B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1345720A (en) * | 2000-09-29 | 2002-04-24 | 中国科学院上海原子核研究所 | Process for preparing trifluoromethyl sulfoacid 2-trimethylammonium-4,5-dimethoxy-benzaldehyde |
| JP2016204314A (en) * | 2015-04-23 | 2016-12-08 | 国立研究開発法人理化学研究所 | Compound and method for producing 4-boronophenylalanine derivative |
Non-Patent Citations (2)
| Title |
|---|
| "Reductive Amination of [1sF]Fluorobenzaldehydes: Radiosyntheses of [2-18F]- and [4-lsF]Fluorodexetimides";Alan A. Wilson et al;《Journal of Labelled Compoundr and Radiophannaceuticals》;19901231;第10卷;第1189-1199页 * |
| "Synthesis, radiofluorination, and preliminary evaluation of the potential 5‐HT2A receptor agonists [18F]Cimbi‐92 and [18F]Cimbi‐150";Fraser Graeme Edgar et al;《J Label Compd Radiopharm.》;20170823;第60卷;第586-591页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108409759A (en) | 2018-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108299482B (en) | F-BPA and intermediate synthesis method, intermediate and application thereof | |
| CN112807276B (en) | Preparation method and application of pyridazinone myocardial perfusion PET radiopharmaceutical | |
| CN109384806B (en) | A [ 2 ]18F]Novel preparation method of FBPA (FBPA) | |
| JP5732198B2 (en) | Method for producing radioactive fluorine-labeled organic compound | |
| CN113354669B (en) | Boron carrier for tumor diagnosis and treatment integration, preparation method and application thereof | |
| CA3041113A1 (en) | Compositions, methods, and systems for the synthesis and use of imaging agents | |
| CN114736112A (en) | Preparation method and application of PET imaging agent for myocardial metabolism | |
| CN114773179B (en) | Preparation method of compound I liquid composition and application of compound I liquid composition in myocardial metabolism PET imaging | |
| EP1854781A1 (en) | Radioactive halogen-labeled phenyloxyaniline derivatives | |
| CN109776587B (en) | Glutamine boron trifluoride analogue with prolonged carbon chain | |
| CN102452951B (en) | Agomelatine and pharmaceutical composition thereof | |
| CN108358958B (en) | Intermediate, intermediate synthesis method and application | |
| CN108409759B (en) | Intermediate, intermediate synthesis method and application | |
| CN114890866B (en) | Beta-elemene halogenate and preparation method thereof | |
| Zijlstra et al. | Synthesis and in vivo distribution in the rat of several fluorine-18 labeled N-fluoroalkylaporphines | |
| CN105348309B (en) | F-BPA nucleophilic synthesis method | |
| CN114796534A (en) | Liquid composition containing compound I, preparation method and application | |
| CN108409760A (en) | Intermediate, intermediate synthetic method and application | |
| CN115724866A (en) | Boron carrier for tumor diagnosis and treatment integration, preparation method and application thereof | |
| TW202146058A (en) | Radiolabeled boron-containing compound, preparation method and application capable of being used as imaging agent for medical imaging and drug for boron neutron capture therapy | |
| CN114507234A (en) | 11C-labeled OSI-027 compound and preparation method and application thereof | |
| WO2006121035A1 (en) | Process for producing organic compound labeled with radioactive halogen | |
| CN111362828A (en) | A kind of18F-labeled fluoropropionylated ornithine as well as preparation method and application thereof | |
| Jalilian et al. | Synthesis of a [18F] labeled chelidonine derivative as a possible antitumor agent | |
| CN114805109B (en) | Efficient preparation method of fluoro [18F ] sand fenamide and PET imaging agent application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |